Format

Send to:

Choose Destination
See comment in PubMed Commons below
PLoS One. 2014 Feb 3;9(2):e87850. doi: 10.1371/journal.pone.0087850. eCollection 2014.

Pharmacological levels of Withaferin A (Withania somnifera) trigger clinically relevant anticancer effects specific to triple negative breast cancer cells.

Author information

  • 1Laboratory of Protein Chemistry, Proteomics and Epigenetic Signaling (PPES), Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.
  • 2Center of Medical Genetics, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium ; Center for Oncological Research (CORE), Laboratory of Cancer Research and Clinical Oncology, Department of Oncology, University of Antwerp, Antwerp, Belgium.
  • 3Nuclear Receptor Signaling Unit, Cytokine Receptor Laboratory, VIB Department of Medical Protein Research, Ghent University, Ghent, Belgium.
  • 4Center for Oncological Research (CORE), Laboratory of Cancer Research and Clinical Oncology, Department of Oncology, University of Antwerp, Antwerp, Belgium.
  • 5Laboratory of Experimental Cancer Research (LECR), Department of Radiation Therapy and Experimental Cancer Research, Ghent University, Ghent, Belgium.
  • 6Laboratory of Eukaryotic Gene Expression and Signal Transduction (LEGEST), Ghent University, Ghent, Belgium.
  • 7Center of Medical Genetics, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium ; StatUa Center for Statistics, University of Antwerp, Antwerp, Belgium.
  • 8Center of Medical Genetics, Department of Biomedical Sciences, University of Antwerp, Antwerp, Belgium.

Abstract

Withaferin A (WA) isolated from Withania somnifera (Ashwagandha) has recently become an attractive phytochemical under investigation in various preclinical studies for treatment of different cancer types. In the present study, a comparative pathway-based transcriptome analysis was applied in epithelial-like MCF-7 and triple negative mesenchymal MDA-MB-231 breast cancer cells exposed to different concentrations of WA which can be detected systemically in in vivo experiments. Whereas WA treatment demonstrated attenuation of multiple cancer hallmarks, the withanolide analogue Withanone (WN) did not exert any of the described effects at comparable concentrations. Pathway enrichment analysis revealed that WA targets specific cancer processes related to cell death, cell cycle and proliferation, which could be functionally validated by flow cytometry and real-time cell proliferation assays. WA also strongly decreased MDA-MB-231 invasion as determined by single-cell collagen invasion assay. This was further supported by decreased gene expression of extracellular matrix-degrading proteases (uPA, PLAT, ADAM8), cell adhesion molecules (integrins, laminins), pro-inflammatory mediators of the metastasis-promoting tumor microenvironment (TNFSF12, IL6, ANGPTL2, CSF1R) and concomitant increased expression of the validated breast cancer metastasis suppressor gene (BRMS1). In line with the transcriptional changes, nanomolar concentrations of WA significantly decreased protein levels and corresponding activity of uPA in MDA-MB-231 cell supernatant, further supporting its anti-metastatic properties. Finally, hierarchical clustering analysis of 84 chromatin writer-reader-eraser enzymes revealed that WA treatment of invasive mesenchymal MDA-MB-231 cells reprogrammed their transcription levels more similarly towards the pattern observed in non-invasive MCF-7 cells. In conclusion, taking into account that sub-cytotoxic concentrations of WA target multiple metastatic effectors in therapy-resistant triple negative breast cancer, WA-based therapeutic strategies targeting the uPA pathway hold promise for further (pre)clinical development to defeat aggressive metastatic breast cancer.

PMID:
24498382
[PubMed - indexed for MEDLINE]
PMCID:
PMC3912072
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Public Library of Science Icon for PubMed Central
    Loading ...
    Write to the Help Desk